EX-99.4 5 phvs-ex99_4.htm EX-99.4

Slide 1

Pioneering science for patient choice Corporate Presentation September 2024 Exhibit 99.4

Slide 2

Disclaimer This Presentation contains certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-looking statements including, without limitation, statements containing the words “believe,” “anticipate,” “expect,” “estimate,” “may,” “could,” “should,” “would,” “will,” “intend” and similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Such forward-looking statements involve unknown risks, uncertainties and other factors which may cause our actual results, financial condition, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, uncertainty in the outcome of our interactions with regulatory authorities, including the FDA, the expected timing, progress, or success of our clinical development programs, especially for deucrictibant, which are in late-stage global clinical trials, our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, and CHAPTER-1 Phase 2 studies in ongoing and future nonclinical studies and clinical trials, risks arising from epidemic diseases such as the COVID-19 pandemic, which may adversely impact our business, nonclinical studies, and clinical trials, the outcome and timing of regulatory approvals, the value of our ordinary shares, the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future, our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates, our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products, our ability to market, commercialize and achieve market acceptance for our product candidates, our ability to raise capital when needed and on acceptable terms, regulatory developments in the United States, the European Union and other jurisdictions, our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others, our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws, our ability to successfully remediate the material weaknesses in our internal control over financial reporting and to maintain an effective system of internal control over financial reporting, changes and uncertainty in general market, political and economic conditions, including as a result of inflation and the current conflict between Russia and Ukraine, the Hamas attack against Israel and the ensuing war, and the other factors described under the headings "Cautionary Statement Regarding Forward-Looking Statements" and "Item 3. Key Information--D. Risk Factors" in our Annual Report on Form 20-F and other periodic filings with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This presentation includes data for an investigational product not yet approved by regulatory authorities. Certain information contained in this Presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this Presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

Slide 3

FDA orphan drug designation1 Robust IP on CoM (granted in multiple territories, initial term to 2038) and formulations2,3 DEUCRICTIBANT Pioneering science for patient choice for hereditary angioedema (HAE) Source: 1U.S. FDA OOPD listing. 2World Intellectual Property Organization. 3European Patent Office. 4Lesage et al. Int. Immunopharmacology, 2022. 5Riedl MA et al. AAAAI 2024. 6Maurer M et al. AAAAI 2023. 7Riedl MA et al. BKS 2024. 8Maurer M et al. BKS 2024. 9Riedl MA at al. BKS 2024. 10IQVIA predictions. 11Evaluate Pharma Uptake Curves 2008-2023. This presentation includes data for an investigational product not yet approved by regulatory authorities. TWO LATE-STAGE PROGRAMS LARGE GLOBAL HAE MARKET STRONG FUNDAMENTALS Deucrictibant is an orally available small molecule targeting the validated bradykinin B2 receptor4 Results from randomized Phase 2 trials 5,6 and their ongoing extensions7,8 demonstrate a differentiated profile for both preventing and treating HAE attacks with injectable-like efficacy, rapid onset of action, a favorable tolerability profile, and oral convenience over current standard of care9 for people living with HAE Predicted $5.2B market in 203610 While people living with HAE appear satisfied with their treatment, history has shown that the availability of a more efficacious, better-tolerated and/or more convenient alternative drives a dynamic switch to the better product11 Internationally, the long-term prevention market is likely to grow significantly10 Two pivotal Phase 3 studies designed to differentiate current standard of care in both prophylaxis and on-demand treatments Accomplished team with track record in HAE drug development and commercialization Approximately €344M cash and cash equivalents as of June 30, 2024

Slide 4

Median: 14 attacks/year Females: 19 (range: 2-165 attacks/y) Males: 9 (range: 1-42 attacks/y) HAE: A rare, life-long genetic condition with significant burden Source: 1Betschel SD, et al. J Allergy Clin Immunol Pract. 2023. 2Christiansen SC, et al. Ann Allergy Asthma Immunol. 2023. 3Bork K et al. Allergy Asthma Clin Immunol. 2021. 4Lumry WR Front. Med. 2018. 5Nordenfelt P et al. Acta Derm. Venereol 2016. This presentation includes data for an investigational product not yet approved by regulatory authorities. Unpredictable attacks | Frequency, location, severity1 Often, unknown triggers1,2 If untreated, attacks may last up to 5 days3 Painful and debilitating | Leading to hospitalization1 Potentially life-threatening due to asphyxiation1 Rare | 1:30,000 to 1:80,000 individuals globally4 Approximately 8,000 people living with HAE in the U.S. 4 Approximately 15,000 people living with HAE in Europe4

Slide 5

In the U.S., significant growth in the long-term prophylaxis (LTP) and on-demand therapy (ODT) market is expected over the next decade1 Source: 1IQVIA market evolution and company data. 2Evaluate Pharma uptake curves 2008-2023. 3SEC filings (BioCryst, CSL Behring, Pharming, Takeda). This presentation includes data for an investigational product not yet approved by regulatory authorities. Growth expected to be driven by: New options Increased convenience Increased treatment rate Value of on-demand1-3 $850m >$1,200m >2% CAGR 22% 38% 24% ~40% share by person Growth expected to be driven by: New options Increased convenience Continued paradigm shift from ODT to LTP Value of prophylaxis1-3 $1,869m $4,000m 6% CAGR 58% 21% ~50% share by person LTP to further grow as the dominant treatment paradigm in the US market through to 20361 2022 LTP 69% ODT 31% 2036 LTP 77% ODT 23% HAE market growth will be driven by increased efficacy and convenience of new therapies

Slide 6

453 pts 384 pts 339 pts 329 pts Despite treatment satisfaction, the U.S. HAE market is dynamic, with people actively seeking a better1 product 1Treatment selection is driven by physicians and patient preference. Source: 2Evaluate Pharma uptake curves 2008-2023 3SEC filings (BioCryst, CSL Behring, Pharming, Takeda). 4U.S. Chart Audit 2023. This presentation includes data for an investigational product not yet approved by regulatory authorities. Across ~7,000 people with HAE, there were over >1,500 unique counts of treatment initiation in 20234 Preference for convenient administration ODT-only to LTP switches dominate Most LTP gains went to Takhzyro and Orladeyo U.S. HAE switches, gains  and losses 3 -36 +55 +70 +52 # of new Rx 66.4% 59.4% 60.2% 57.2% 33.6% 40.6% 39.8% 42.8% Q1'23 Q2'23 Q3'23 Q4'23 -0 -100 -200 -300 -400 -500 Losses (people) 32.6% 44.6% 43.0% 41.2% 67.4% 55.4% 57.0% 58.8% 417 pts 439 pts 400 pts 391 pts Q1'23 Q2'23 Q3'23 Q4'23 0 100 200 300 400 500 Gains (people) ODT LTP Evolution of HAE product sales1,2 People actively switch therapies2,3: first-to-market is no guarantee for long-term market leadership

Slide 7

People living with HAE are seeking a life not defined by their condition nor burdened by its management1 Source: 1Lumry WR et al. Allergy Asthma Proc. 2020. 2Geba et al, J Drug Access.2021. 3U.S. Chart Audit 2023 This presentation includes data for an investigational product not yet approved by regulatory authorities. People living with HAE actively switch between products3, seeking improvement in efficacy, safety/tolerability, and convenience Efficacy is a prime driver… but safety and tolerability cause exploration of alternatives… …while convenience is a key driver for overall preference2

Slide 8

Bradykinin B2 receptor antagonism is a foundational mechanism to treat and prevent bradykinin-mediated angioedema attacks1,2 Directly blocks the main mediator of swelling and inflammation1,3 Has the potential to prevent or treat bradykinin-mediated angioedema irrespective of the source of bradykinin4-6 Source: 1Maurer M, et al. Allergy. 2022. 2Zuraw BL World Allergy Orphan J. 2010. 3Lumry WR et al. Allergy Asthma Proc. 2020. 4Riedl MA et al. AAAAI 2024. 5Maurer M et al. AAAAI 2023. 6Petersen RS et al. J Allergy Clin Immunol. 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities. cHMWK Inactive fragments HMWK ACEi + Prekallikrein FXII Plasminogen Plasmin FXIIa tPA Kininase II /ACE Plasma kallikrein KNG1 F12 PLG C1-INH Bradykinin B2 receptor Deucrictibant Bradykinin Angioedema

Slide 9

Deucrictibant has the potential to become a preferred therapy for people living with HAE *To be confirmed with clinical data from Phase 3 studies Source: 1Company data: single-dose cross-over PK study in healthy volunteers (n=14) under fasting conditions. 2Lesage A et al, IDDST 2024. 3Crabbe et al, AAAAI 2021. 4Maurer M et al, AAAAI 2023. This presentation includes data for an investigational product not yet approved by regulatory authorities. Rapidly reaches therapeutic exposure within 15-30 minutes4, making it optimal for on-demand oral treatment of HAE attacks* DEUCRICTIBANT immediate-release (IR) capsule rapid absorption3 deucrictibant Maintains sustained therapeutic exposure over 24 hours2 from day one, allowing for once-daily oral treatment to prevent HAE attacks* DEUCRICTIBANT extended-release (XR) tablet sustained absorption1 Two oral products with the same active ingredient for the prevention and treatment of HAE attacks

Slide 10

Deucrictibant differentiated profile for LTP and ODT Sources: 1Company research. 2Leasge et al, IDDST 2024. 3Groen K et al, ACAAI 2022. 4Li H et al, EAC 2024. 5Maurer M et al. HAEi Workshop, 2022. 6Maurer M et al, AAAAI 2023. 7Riedl et al, WSAAI 2024. 8Maurer M et al. BKS 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities. Rapid Absorption Within 15-30 minutes6, deucrictibant IR reaches therapeutic exposure resulting in the halt of attack progression within 30 minutes7 Longer Effective Exposure A longer effective exposure results in a high rate of single-dose attack resolution8 Single Oral Pill Specific formulations allow for once-daily dosing3 (XR for LTP) or rapid, single-dose resolution4 of HAE attacks (IR for ODT) Oral ODT or LTP Formulations Deucrictibant is the only HAE therapy1 in development that allows for oral administration in both prophylaxis and on-demand2 Rapid to Steady State Deucrictibant XR has the potential to achieve steady state within 2-3 days5, providing protection against HAE attacks on the initial day3 of LTP initiation LTP ODT

Slide 11

Wholly-owned pipeline focused on bradykinin B2 receptor mechanism LTE: long-term extension, OLE: open-label extension This presentation includes data for an investigational product not yet approved by regulatory authorities. MOLECULE FORMULATION INDICATION deucrictibant Undisclosed PHAXXX HAE On-Demand HAE Prophylaxis Next Milestone Complete Enrollment REGISTRATION PHASE 3 PRECLINICAL PHASE 1 PHASE 2 Undisclosed Immediate-Release Capsule Extended-Release Tablet OLE Initiation LTE

Slide 12

On-Demand Treatment (ODT) Long-Term Prophylaxis (LTP) Deucrictibant clinical development for LTP and ODT OLE: open-label extension. LTE: long-term extension. Source: 1NCT05047185. 2NCT04618211. 3NCT05396105. 4NCT06343779. Phase 22 Complete Phase 2/3 LTE3 Ongoing Phase 3 pivotal4 Ongoing Phase 21 Part 1: randomized controlled primary analysis (complete) Part 2: open-label extension (ongoing) Phase 3 pivotal Start-up Phase 3 OLE Start-up This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 13

Efficacy With injectable-like efficacy and oral convenience, deucrictibant shows potential to become a preferred therapy to manage HAE OLE: open-label extension. LTE: long-term extension. PGI-C: patient global impression of change. PGI-S: patient global impression of severity. Source: 1Riedl MA et al. BKS 2024. 2Valerieva A et al. EAACI 2024. 3Magerl M et al. BKS 2024. 4Riedl MA et al. AAAAI 2024. 5Maurer M et al. BKS 2024. 6Maurer M et al. AAAAI 2023. This presentation includes data for an investigational product not yet approved by regulatory authorities. Long-Term Prophylaxis (LTP) Potential preferred option for LTP Safety & Tolerability Quality of Life Formulation Efficacy Early-onset attack reduction sustained for over one year in ongoing OLE study1 Improvement in disease control and health-related quality of life paralleled attack reduction in Phase 22,3 Phase 2 safety and tolerability profile confirmed in ongoing OLE study1,4 Commercial formulation for once-daily dosing ready for Phase 3     On-Demand Treatment (ODT) Potential preferred option for ODT Safety & Tolerability Onset of symptom relief with median PGI-C “a little better” ~ 1.1 hour Symptom resolution with PGI-S “none” ~ 11.5 hours in ongoing LTE study5 85.8% of attacks achieved complete symptom resolution within 24 hours in ongoing LTE; 90.2% of which with single dose5 Phase 2 safety and tolerability profile confirmed in ongoing LTE study5,6  

Slide 14

Long-Term Prophylaxis Deucrictibant extended-release tablets

Slide 15

On-Demand Treatment (ODT) Long-Term Prophylaxis (LTP) Deucrictibant clinical development for LTP OLE: open-label extension. LTE: long-term extension. Source: 1NCT05047185. 2NCT04618211. 3NCT05396105. 4NCT06343779. Phase 22 Complete Phase 2/3 LTE3 Ongoing Phase 3 pivotal4 Ongoing Phase 21 Part 1: randomized controlled primary analysis (complete) Part 2: open-label extension (ongoing) Phase 3 pivotal Start-up Phase 3 OLE Start-up This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 16

Positive top-line data from CHAPTER-1, a Phase 2 prophylactic study of deucrictibant in HAE, announced in December 20231 92.3% reduction in occurrence of moderate and severe attacks*  92.6% reduction in occurrence of attacks treated with on-demand medication* Clinically meaningful results across primary, secondary, and health-related quality of life endpoints  Deucrictibant well-tolerated at both doses  *40 mg/day deucrictibant treatment group; %reduction in monthly attack rate is based on a Poisson regression model. All attacks reported herein are investigator-confirmed; attack rate is number of attacks per month of exposure, also referred to as time-normalized number of attacks; all statistical analyses comparing deucrictibant and placebo are made without adjustment for multiplicity. Source: 1Aygören-Pürsün E et al. EAACI 2024. Primary endpoint met: 84.5% (p=0.0008) reduction in monthly attack rate versus placebo* This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 17

CHAPTER-1: Two-part, Phase 2 study of deucrictibant for long-term prophylaxis of HAE attacks HAE, hereditary angioedema; OLE, open-label extension; IR, immediate-release; R, randomization; RCT, randomized controlled trial. aDeucrictibant IR capsule, 10 mg twice daily. bDeucrictibant IR capsule, 20 mg twice daily. CHAPTER-1 is a Pharvaris-sponsored clinical trial. ClinicalTrials.gov identifier: NCT05047185. Accessed August 14, 2024. https://www.clinicaltrials.gov/study/NCT05047185. This presentation includes data for an investigational product not yet approved by regulatory authorities. Placebo Deucrictibant 20 mg/daya Deucrictibant 40 mg/dayb Part 1 (RCT): Double-blind treatment period (12 weeks) Screening R End-of-study visit Deucrictibant 40 mg/dayb Part 2 (OLE): Open-label treatment period Open-Label Extension (OLE) Evaluate safety (primary objective) and efficacy of deucrictibant administered for long-term prophylaxis against HAE attacks 100% of CHAPTER-1 completers continued in OLE Data from RCT and OLE also presented for RCT completers for direct comparison

Slide 18

Balanced demographics and baseline characteristics BMI, body mass index; HAE, hereditary angioedema; IR, immediate-release. N = number of randomized participants; RCT, randomized controlled trial. aDeucrictibant IR capsule, 10 mg twice daily. bDeucrictibant IR capsule, 20 mg twice daily. c1 month = 4 weeks. This presentation includes data for an investigational product not yet approved by regulatory authorities. RCT OLE 40 mg/dayb (N=30) Placebo (N=11) 20 mg/daya (N=11) 40 mg/dayb (N=12) Age (years), mean (SD)  41.4  38.4 40.8  39.1 (14.5) Sex: Male/Female, n (%) 3/8 6/5 4/8 12 (40.0) / 18 (60.0) Race: White, n (%) 11 (100) 11 (100) 12 (100) 30 (100) BMI (kg/m2), mean 26.7 29.5 25.4 27.4 HAE type, n Type 1 10 9 12 27 Type 2 1 2 0 3 Baseline monthlyc HAE attack rate Mean 1.9 2.1 2.5 2.2 Median (min, max) 1.7 (0.7, 3.7) 1.7 (1.0, 5.3) 1.7 (1.0, 6.7) 1.7 (0.7, 6.7) Randomized baseline monthlyc HAE attack rate categories, n (%) 1 to <2 attacks 6 (54.5) 7 (63.6) 7 (58.3) 18 (60.0) 2 to <3 attacks 3 (27.3) 1 (9.1) 1 (8.3) 3 (10.0) ≥3 attacks 2 (18.2) 3 (27.3) 4 (33.3) 9 (30.0) 30 participants in the OLE received deucrictibant 40 mg/day with a mean (SD) treatment duration of 12.83 (5.03) months

Slide 19

Summary of safety data in LTP ongoing open-label extension IR, immediate-release; TEAE, treatment emergent adverse event. N = number of participants who received at least 1 dose of blinded study treatment. aDeucrictibant IR capsule, 20 mg twice daily. bDeucrictibant IR capsule, 10 mg twice daily. This presentation includes data for an investigational product not yet approved by regulatory authorities. Adverse events Placebo to 40 mg/daya (N=9) 20 mg/dayb to 40 mg/daya (N=11) 40 mg/daya to 40 mg/daya (N=10) Total (N=30) Events Participants, n (%) Events, n Participants, n (%) Events, n Participants, n (%) Events, n Participants, n (%) Events, n TEAEs 5 (55.6) 25 7 (63.6) 31 6 (60.0) 16 18 (60.0) 72 Treatment-related TEAEs 1 (11.1) 1* 0 0 0 0 1 (3.3) 1 Serious TEAEs 0 0 1 (9.1) 1 1 (10.0) 1 2 (6.7) 2 Treatment-related serious TEAEs 0 0 0 0 0 0 0 0 TEAEs leading to study drug discontinuation, study withdrawal, or death 0 0 0 0 0 0 0 0 No treatment-related serious or severe TEAEs No treatment-related TEAEs in laboratory parameters, vital signs, or ECG findings No TEAEs leading to treatment discontinuation, study withdrawal, or death * One event of tooth discoloration is reported as treatment-related TEAEs

Slide 20

Continuing deucrictibant treatment sustained the early-onset attack reduction for over one year IR, immediate release; OLE, open label extension; RCT, randomized controlled trial. N = number of participants randomized in each treatment group in Part 1 of the study. N’ = number of participants in the OLE. a1 month = 4 weeks. bDeucrictibant IR capsule, 10 mg twice daily. cDeucrictibant IR capsule, 20 mg twice daily. This presentation includes data for an investigational product not yet approved by regulatory authorities. Placebo (N=11) 20 mg/dayb (N=11) 40 mg/dayc (N=12) RCT 40 mg/dayc (N’=30) OLE 79.3% reduction; P=0.0009 84.5% reduction; P=0.0008 Attack ratea (LS mean) In the open-label extension up to 18 months: 93% attack rate reduction from baseline Median attack rate = 0 for every month 99% of days symptom free

Slide 21

Occurrence of moderate and severe attacks remained low in the OLE treatment period IR, immediate release; LS, least squares; OLE, open-label extension; RCT, randomized controlled trial. N = number of participants randomized in each treatment group in the RCT. N’ = number of participants in the OLE. LS mean estimates of attack rate are based on Poisson regression models adjusted for baseline attack rate and time on treatment. No multiplicity adjustment was applied. The P-values in this figure are nominal. aBased on time-normalized number of attacks per 4 weeks. bDeucrictibant IR capsule, 10 mg twice daily. cDeucrictibant IR capsule, 20 mg twice daily. This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 22

On average less than one attack per year per participant was treated with rescue medication IR, immediate release; LS, least squares; OLE, open-label extension; RCT, randomized controlled trial. N = number of participants randomized in each treatment group in the RCT. N’ = number of participants in the OLE. LS mean estimates of attack rate are based on Poisson regression models adjusted for baseline attack rate and time on treatment. No multiplicity adjustment was applied. The P-values in this figure are nominal. aBased on time normalized number of attacks per 4 weeks. bDeucrictibant IR capsule, 10 mg twice daily. cDeucrictibant IR capsule, 20 mg twice daily. This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 23

Improvements in disease control and health-related quality of life paralleled attack reduction during deucrictibant treatment1,2 AE-QoL, Angioedema Quality of Life Questionnaire; 4-week AECT, Angioedema Control Test (4-week recall period); IR, immediate-release; RCT, randomized controlled trial. N = number of participants with AECT and AE-QoL data at week 12. aDeucrictibant IR capsule, 10 mg twice daily. bDeucrictibant IR capsule, 20 mg twice daily. Source: 1Magerl M et al. 2024 BKS. 2Zanichelli A et al. ITACA 2024. 3Maurer M et al. 2022 Allergy. The goals of HAE treatment are to achieve complete control of the disease and to normalize people’s lives3 This can currently only be achieved by long-term prophylaxis (LTP) AECT score1 AE-QoL score1 This presentation includes data for an investigational product not yet approved by regulatory authorities. 90% well-controlled participants in both deucrictibant groups vs. 37.5% in placebo group at week 12 ‘Functioning’ and ‘fear and shame’ domains showed greatest improvements at Week 12

Slide 24

Deucrictibant shows greater patient satisfaction versus placebo across effectiveness and global satisfaction (TSQM instrument) IR, immediate release; TSQM, Treatment Satisfaction Questionnaire for Medication. N′ = number of participants with TSQM results at week 12. aDeucrictibant IR capsule, 10 mg twice daily. bDeucrictibant IR capsule, 20 mg twice daily. This presentation includes data for an investigational product not yet approved by regulatory authorities. Placebo (N′=8) 20 mg/daya (N′=10) 40 mg/dayb (N′=10)

Slide 25

Positive Phase 3 data could position deucrictibant to become a preferred LTP with injectable-like efficacy and the oral convenience of a daily tablet § Crossover, 12 weeks/treatment. §§ Crossover, 16 weeks/treatment (results reported for weeks 3-16 for each treatment arm). † Parallel-arms, 26 weeks. †† Parallel-arms, 24 weeks. ¶ Parallel-arms, 25 weeks. ‡ Parallel-arms, 12 weeks. # vs. placebo. ¶¶ Weeks 5-25. ¤ vs. RCT Part 1 baseline. 1. Cinryze® US PI, Feb 2023. 2. Longhurst H et al. 2017 N Engl J Med. 3. Haegarda® US PI, Jan 2022. 4. Takhzyro® US PI, Feb 2023. 5. Banerji A et al. 2018 JAMA. 6. Zuraw B et al. 2021 J Allergy Clin Immunol. 7. Orladeyo® US PI, Nov 2023. 8. Craig TJ et al. 2023 Lancet. 9. Riedl MA et al. 202 N Engl J Med. 10. Aygören-Pürsün E et al. 2024 EAACI. 11 Aygören-Pürsün E et al. 2024 KS. 12. Riedl MA et al. 2024 BKS. This presentation includes data for an investigational product not yet approved by regulatory authorities. Mean monthly attack reduction vs. placebo ≥50% attack reduction ≥70% attack reduction Cinryze® (pdC1INH) Haegarda® (pdC1INH) Takhzyro® (lanadelumab) Orladeyo® (berotralstat) garadacimab 89%8 95% vs. 33%8 92% vs. 17%8 74% vs. 8%8 62% vs. 0%8 71-85%1 - - - - 84%2 90%#2,3 83%#2,3 58%#2,3 40% vs. 0%2,3 73-87%4 100-100% vs. 32%4,5 76-89% vs. 10%4,5 55-67% vs. 5%4,5 31-44% vs. 2%4,5 44%6,7 58% vs. 25%6,7 50% vs. 15%6,7 23% vs. 8%6,7 10% vs. 2.5%6 ≥90% attack reduction % patients attack-free vs. placebo Anti-FXIIa mAb Plasma kallikrein inhibitor Anti-plasma kallikrein mAb Plasma-derived C1INH Plasma-deriveed C1NH Mechanism of Action donidalorsen 55-81%9 83-93% vs. 27%¶¶9 65-92% vs. 18%¶¶9 48-62% vs. 9%¶¶9 35-53% vs. 9%¶¶9 Plasma kallikrein inhibitor deucrictibant Ph 3† Ph 3†† (150mg) Ph 3† (300mg q2w / q4w) Ph 3§§ (60 IU/Kg) Ph 3§ (500 U, 1,000 U) Clinical Trial(s) Ph 3¶ (80 mg q4w, q8w) Ph 2‡ (40mg) Ph 2/3 LTE Bradykinin B2 receptor antagonist 85%10,11 90% vs. 18%11 80% vs. 18%11 60% vs. 0%11 40% vs. 0%11 93%¤12 pending publication pending publication pending publication pending publication Mean reduction in use of ODT vs. placebo 88%8 - 89%2 74-87%4 54%7 67-92%¶¶9 93%10,11 pending publication

Slide 26

CHAPTER-3 and CHAPTER-4 Clinical Studies

Slide 27

Commercial XR formulation maintains exposure above therapeutic level for at least 24 hours Extended-release matrix controls release and absorption of compound in small intestine as well as in colon Supports once-daily dosing while maintain exposure more consistently versus twice-daily IR (used in proof-of-concept Phase 2 CHAPTER-1 study) Formulation patent applications filed with broad coverage of worldwide pharmaceutical markets Source: Company data: single-dose cross-over PK study in healthy volunteers (n=14) under fasting conditions This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 28

CHAPTER-3 study: A global Phase 3 study of prophylactic treatment of angioedema attacks in people with HAE Target enrollment of approximately 81 adolescents and adults living with HAE Initiating by year-end 2024 Study objectives Evaluation and characterization of investigator-confirmed HAE attacks during 24-week treatment period Incidence of treatment-emergent adverse events Evaluation of deucrictibant XR pharmacokinetics Measure of change in participant-reported quality of life Rollover to open-label extension This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 29

On-Demand Deucrictibant immediate-release capsules

Slide 30

On-Demand Treatment (ODT) Long-Term Prophylaxis (LTP) Deucrictibant clinical development for ODT OLE: open-label extension. LTE: long-term extension. Source: 1NCT05047185. 2NCT04618211. 3NCT05396105. 4NCT06343779. Phase 22 Complete Phase 2/3 LTE3 Ongoing Phase 3 pivotal4 Ongoing Phase 21 Part 1: randomized controlled primary analysis (complete) Part 2: open-label extension (ongoing) Phase 3 pivotal Start-up Phase 3 OLE Start-up This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 31

Symptom evolution towards relief and resolution Symptom progression Clinical trial endpoints span the entire attack timecourse AMRA, Angioedema Symptom Rating Scale; EoP, end of progression; HAE, hereditary angioedema; IR, immediate release; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity; 1. ClinicalTrials.gov. Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-1). Available at: https://clinicaltrials.gov/study/NCT04618211. Accessed August 2024; 2. Maurer et al. AAAAI 2022, Poster. 3. Riedl et al. ACAAI 2023, Poster. 4. ClinicalTrials.gov. Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-2). Available at: https://clinicaltrials.gov/study/NCT05396105. Accessed August 2024; 5. ClinicalTrials.gov. Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema (RAPIDe-3). Available at: https://clinicaltrials.gov/study/NCT06343779. Accessed August 2024. 6. Maurer et al. EAACI 2024, Poster. This presentation includes data for an investigational product not yet approved by regulatory authorities. Time (not to scale) Clinical manifestations Treatment with deucrictibant IR End of progression Onset of symptom relief Complete symptom resolution RAPIDe-11,2,3 RAPIDe-35,6 AMRA all 3 items ≤10 PGI-S “none”; AMRA all 3 items ≤10 Time to EoP by PGI-C Onset of HAE attack AMRA-3 ≥30% reduction Primary endpoint PGI-C “a little better” Substantial symptom relief AMRA-3 ≥50% reduction RAPIDe-24 PGI-S “none”; AMRA all 3 items ≤10 PGI-C “a little better” AMRA ≥30% reduction; PGI-C “better”; PGI-S ≥1 point reduction; AMRA ≥50% reduction PGI-C “better”; PGI-S ≥1 point reduction; AMRA ≥50% reduction Time to EoP by AMRA Post-hoc

Slide 32

Patient-reported outcomes (PRO) assessments Source: Riedl MA et al. BKS 2024 This presentation includes data for an investigational product not yet approved by regulatory authorities. Patient Global Impression of Change PGI-C Much worse Worse A little worse Same A little better Better Much better Patient Global Impression of Severity Very severe Severe Moderate Mild None PGI-C Angioedema syMptom Rating scAle (AMRA) 100 Worst possible symptoms 0 No symptoms (skin pain, skin swelling, abdominal pain) AMRA

Slide 33

RAPIDe-1, a Phase 2 on-demand study of deucrictibant in HAE End of symptom progression in 25-26 minutes* (based on AMRA-3)†2 Onset of symptom relief occurs in 2.4 hours* (≥30% reduction in AMRA-3)1 5-fold reduction in rescue medication use*1 81.7% of attacks achieved symptom resolution in 24 hours* (TOS PRO of “a lot better or resolved” in all symptom complexes) †3 Deucrictibant well-tolerated at all doses1 *pooled 10, 20, 30 mg deucrictibant treatment group †based on post-hoc analysis Source: 1Maurer M et al. ACAAI 2023. 2 Riedl MA et al. ACAAI 2023. 3Li H et al. EAC 2024. Primary endpoint met: deucrictibant IR significantly reduced attack symptoms versus placebo*1 This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 34

RAPIDe-2 study design and objective1 IR, immediate-release. aIncluding laryngeal attacks (without breathing difficulties). Source: 1Maurer M et al. BKS 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities. Objective: To evaluate the long-term safety and efficacy of orally administered deucrictibant immediate-release capsule for the treatment of HAE attacksa Part A: Double-blind phase Part B: Open-label phase RAPIDe-1 participants deucrictibant IR 10 mg deucrictibant IR 20 mg deucrictibant IR 30 mg deucrictibant IR 20 mg RAPIDe-3 participants Placebo deucrictibant IR 20 mg Placebo deucrictibant IR 20 mg

Slide 35

Baseline characteristics1 265 attacks from 17 patients included in the mITT efficacy analysis set (data cutoff: 01 March 2024) 337 attacks from 19 patients included in the safety analysis set (data cutoff: 10 June 2024) 7 of 337 attacks were laryngeal BMI, body mass index; HAE, hereditary angioedema; IR, immediate-release; SD, standard deviation. aNumber by the cutoff date of 10 June 2024. Source: 1Maurer M et al. BKS 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities. Deucrictibant IR capsule (All doses) Number of attacks treateda 337 Number of participantsa 19 Age in years, mean (SD) 42.7 (17.6) Sex: Male/female, n (%) 7 (36.8) / 12 (63.2) Race: White/other 18 / 1 BMI, mean (SD) 27.0 (3.8) Years since HAE diagnosis, mean (SD) 21.7 (15.2) HAE type, n (%) HAE-1 17 (89.5) HAE-2 2 (10.5)

Slide 36

Summary of safety profile1 No treatment-related serious or severe TEAEs No treatment-related TEAEs in laboratory parameters, vital signs, or ECG findings were reported No TEAEs leading to treatment discontinuation, study withdrawal, or death IR, immediate-release; TEAE, treatment-emergent adverse event (defined as AE occurring during time window from first study drug administration; TEAEs within 5 days post-treatment were analyzed); N= Number of participants treated with study drug, N’ = Number of attacks treated with study drug. Data snapshot for safety analysis population: 10 June 2024. Source: 1Maurer M et al. BKS 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities. Adverse events Deucrictibant IR capsule (All doses) Number of patients (safety analysis population) N=19 Number of attacks treated N’=337 Attacks with any TEAE, n (%) 13 (3.9) Treatment-related TEAEs, n 0 Serious TEAEs, n 1 Treatment-related serious TEAEs, n 0 TEAEs leading to study drug discontinuation, study withdrawal, or death, n 0

Slide 37

Rapid median onset of symptom relief at ~1.1 hours: 98.5% of attacks achieved onset of symptom relief by 12 hours1 Time to onset of symptom relief is defined as PGI-C rating of at least 'a little better' for two consecutive timepoints post-treatmenta PGI-C, Patient Global Impression of Change. aSymptom relief is also considered as achieved if PGI-C rating reached at least a 'little better' at the last scheduled time point (48 h) provided no rescue medication used within 48h after the last time point. The time is censored at the time of the last post-treatment PGI-C assessment prior to intake of HAE rescue medication, or a medication not allowed for treating an attack. Source: 1Maurer M et al. BKS 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities. Proportion of attacks with symptom relief by PGI-C (%) Median time to onset of symptom relief: ~1.1 hours (95% CI: 1.0, 1.2)

Slide 38

Rapid median reduction in attack severity at 2.6 hours: 97.7% of attacks achieved a reduction in severity by 12 hours1 Reduction in attack severity is defined as achieving ≥1 point reduction in PGI-S from pre-treatment for two consecutive time pointsa PGI-S, Patient Global Impression of Severity. aReduction in attack severity is also considered as achieved if ≥ 1 point reduction in PGI-S from pre-treatment at the last scheduled time point (48 h) provided no rescue medication used within 48h after the last time point. b261 attacks have non-missing pre-treatment PGI-S. Source: 1Maurer M et al. BKS 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities. Median time to reduction in attack severity: 2.6 hours (95% CI: 2.0, 2.9) Proportion of attacks with reduction in attack severity by PGI-S (%)

Slide 39

Median attack resolution time 11.5 hours: 85.8% of attacks completely resolved within 24 hours (90.2% of which with one only dose)1 Time to complete attack resolution is defined as the time to post-treatment PGI-S rating achieving 'none' PGI-S, Patient Global Impression of Severity. a261 attacks have non-missing pre-treatment PGI-S. Source: 1Maurer M et al. BKS 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities. Median time to complete attack resolution: 11.5 hours (95% CI: 11.0, 13.0) Proportion of attacks with complete resolution by PGI-S (%) 1 dose of deucrictibant IR capsule 2 doses of deucrictibant IR capsule Attacks treated with 1 or 2 doses of deucrictibant prior to achieving complete attack resolution (% of 224 attacks)

Slide 40

Mixed-methods study: Non-interventional collection of HAE attack symptoms assessments following treatment with standard of care Note: Standard of care was icatibant or plasma derived/recombinant C1-Inhibiitor This presentation includes data for an investigational product not yet approved by regulatory authorities. Participants recruited by HAEA PGI-C, PGI-S, and AMRA-3/ AMRA-5 data collected via mobile app At pre-treatment Every hour up to 4 hours following treatment administration Then at 8, 12, 24, and 48 hours Qualitative interviews with a subset of participants

Slide 41

In a propensity-score-matching analysis, deucrictibant showed favorable symptom relief outcomes versus standard of care1 This presentation includes data for an investigational product not yet approved by regulatory authorities. AMRA, Angioedema syMptom Rating scAle; CI, confidence interval; IR, immediate-release; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. N=73 for both cohorts. Parameters: The first 10 consecutive attacks were selected for each participant; Greedy Nearest Neighbor 1:1 matching was used with Caliper = 0.5; participants were matched for sex, age, baseline attack severity (defined by AMRA score), and exact attack primary location. Source: 1Riedl MA et al. BKS 2024. A. Time to symptom relief defined as PGI-C "A little better" 0 1 2 3 4 6 12 Time (hours) 0 20 40 60 80 100 Proportion of attacks (%) Mixed-methods study cohort (SOC) KM estimate: 2.38 (1.68, 3.10) RAPIDe-2 study cohort (deucrictibant IR capsule) KM estimate: 1.07 (0.98, 1.89) 5 8 C. Time to symptom relief defined as PGI-C "Better" Proportion of attacks (%) 0 8 1 2 5 3 4 6 12 Time (hours) 0 20 40 60 80 100 Mixed-methods study cohort (SOC) KM estimate: 4.49 (3.09, 6.18) RAPIDe-2 study cohort (deucrictibant IR capsule) KM estimate: 2.66 (1.98, 3.55) B. Time to reduction in attack severity defined as PGI-S ≥1 point reduction Proportion of attacks (%) 0 1 2 5 3 4 6 12 Time (hours) 0 20 40 60 80 100 Mixed-methods study cohort (SOC) KM estimate: 4.02 (3.15, 5.19) RAPIDe-2 study cohort (deucrictibant IR capsule) KM estimate: 2.14 (1.93, 2.94) 8 Time to symptom relief in hours, median (95% CI) RAPIDe-2 cohort (deucrictibant; N=73) Mixed-methods cohort (SOC; N=73) A PGI-C – “A little better” 1.07 (0.98, 1.89) 2.38 (1.68, 3.10) B PGI-S – ≥1 point reduction 2.14 (1.93, 2.94) 4.02 (3.15, 5.19) C PGI-C – “Better” 2.66 (1.98, 3.55) 4.49 (3.09, 6.18)

Slide 42

RAPIDe-3 Clinical Study

Slide 43

HAE RAPIDe-31 study enrolling: A global Phase 3 study of on-demand treatment of angioedema attacks in people with HAE-1/2 Target enrollment of approximately 120 adolescents and adults (between 12 and 75 years old) Endpoints Onset of symptom relief Patient Global Impression of Change (PGI-C) rating of at least “a little better” for two consecutive timepoints within 12 hours post-treatment Secondary Time to end of progression of attack symptoms, substantial symptom relief, and symptom resolution PGI-C, Patient Global Impression of Severity (PGI-S), Angioedema syMptom Rating scAle (AMRA) Use of rescue medication Incidence of treatment-emergent adverse events Rollover to open-label extension Adolescent patients receive a non-attack dose for PK sampling prior to randomization. Source: 1Maurer M et al. EAACI 2024. 20 mg capsule This presentation includes data for an investigational product not yet approved by regulatory authorities. Double-blind crossover treatment with two qualifying attacks

Slide 44

Plasma-derived C1NH (23%) - Icatibant (60%) – Recombinant hC1INH (9%) - Other (9%) Positive Phase 3 data could position deucrictibant to become a preferred ODT with rapid-onset and complete symptom resolution with a single oral capsule References on following slide This presentation includes data for an investigational product not yet approved by regulatory authorities. Time to onset of symptom relief (median) Standard of Care Berinert® (pdC1INH), Firazyr® (icatibant), Ruconest® (rhC1INH) - - 2.4 h8 - 4.0 h8 - - 13.5 h8 - PSM Analysis of Mixed Methods Study9 Clinical Trial(s) Time to ≥50% VAS reduction (median) Time to reduction in attack severity (median)d Time to symptom resolution (median) % attacks resolved within 24 h with 1 dose - % attacks treated with 1 dose of study drug (no additional doses of study drug and/or rescue med.) VAS/AMRAa TOSb PGI-Cc VAS/AMRAe TOSf PGI-Sg Mechanism of Action sebetralstat tablet deucrictibant IR capsule 2.4 vs. 8.0 h3 - 2.0 vs. 7.6 h4,5 - - 1.1 h7 3.9 vs. 22.8 h3 - - 2.6 h7 7.5 vs. 42.0 h3 - 5.2 vs. 23.3 h4,5 - - 11.5 h7 75.0% vs. 15.7†6 81.7% vs. 22.4%‖6 90.2%7 - - 1.6-1.8 vs. 6.7 h1 Not reported yet2 7.7-9.3 vs. > 12 h1 - - ≥24.0 vs. >24 h1 42.5-49.5% vs. 27.4%#1 Ph 2 (10mg, 20mg, 30 mg pooled) Ph 2/3 Ext.* (10mg, 20mg, 30mg pooled) Ph 3* (300mg, 600mg) pending publication 86.0%§7 ≤60.2-≤60.9 vs. ≤44.0%1 Bradykinin B2 receptor antagonist Plasma kallikrein inhibitor - - 1.1 h8 - 2.1 h8 - - 12.3 h8 - Ph 2/3 Ext. PSM Analysis (10mg, 20mg, 30mg pooled) -

Slide 45

ODT comparison data references * Non-laryngeal and laryngeal attacks included for treatment with study drug. # Symptom resolution assessed by PGI-S. † Symptom resolution assessed by VAS/AMRA. ‖ Symptom resolution assessed by TOS. a. Time to onset of symptom relief by VAS/AMRA defined as ‘VAS-3 ≥30% reduction from pre-treatment score’ in 3. b. Time to onset of symptom relief by TOS defined as ‘The time point when TOS PRO first reaches at least “A little better” for all symptom complexes affected at baseline, ’and no new symptom in any other symptom complex is reported. Relief is confirmed if the improvement is sustained at 2 consecutive time points’ in 4,5. c. Time to beginning (or onset) of symptom relief by PGI-C defined as ‘beginning of symptom relief as assessed in a time-to-event analysis. The beginning of symptom relief was defined as a rating of “a little better” on the 7-point Patient Global Impression of Change (PGI-C) scale (ratings range from “much better” to “much worse”) at two or more consecutive time points within 12 hours after the first administration of the trial agent’ in 1 and as ‘Patient Global Impression of Change (PGI-C) rating of at least “a little better” for 2 consecutive timepoints by 12 hours post-treatment’ in 7,8. d. Time to reduction in attack severity defined as ‘reduction in the severity of the attack, defined as an improved rating on the 5-point Patient Global Impression of Severity (PGI-S) scale (ratings range from “none” to “very severe”) at two or more consecutive time points within 12 hours after the first administration’ in 1 and ‘achieving ≥1 point reduction in the Patient Global Impression of Severity (PGI-S) from pretreatment for 2 consecutive timepoints by 12 hours post-treatment’ in 7,8. e. Time to symptom resolution by VAS/AMRA defined as ‘all 3 individual VAS items ≤10’ in 3. f. Time to symptom resolution by TOS defined as ‘The time point when TOS PRO first reaches “A lot better or resolved” for all symptom complexes affected at baseline, and no new symptom in any other symptom complex is reported’ in.4,5 g. Time to symptom resolution by PGI-S defined as ‘achieving PGI-S rating of “none” at 24 hours post-treatment’ in 1 and as ‘achieving PGI-S rating of “none” at 24 hours post-treatment’ in 7,8 . 1. Riedl MA et al. 2024 N Engl J Med. 2. https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001226-21/DE (accessed 2 September 2024). 3. Maurer M et al. 2023 AAAAI. 4. Riedl MA et al. 2023 C1INH Workshop. 5. RAPIDe-1 Phase 2 Top-line data presentation, https://ir.pharvaris.com/static-files/733117c4-4632-4bd6-a93b-9484c46e063c (accessed 2 September 2024). 6. Li HH et al. 2024 EAC. 7. Maurer M et al. 2023 BKS. 8. Riedl MA et al. 2024 BKS. 9. Mendivil et al. 2023 UCARE This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 46

Our strategy is to become a market leader in HAE Notes: Aspirational, to be confirmed with Phase 3 clinical data This presentation includes data for an investigational product not yet approved by regulatory authorities. 1 2 4 3 Win the oral LTP market Become preferred LTP Leverage portfolio with B2R antagonist MoA Become standard of care in ODT LTP ODT Both Rooted in a deep commitment to engage with the HAE community

Slide 47

Going Beyond HAE

Slide 48

Deucrictibant: Only compound today1 with the potential to deliver injection-like efficacy orally across both LTP and ODT *To be confirmed with clinical data from Phase 3 studies. **Patient preference varies. Source: 1Company research. 2Company data: target threshold exceeded on first day in single-dose cross-over PK study in healthy volunteers (n=14) under fasting conditions. 3Lesage A et al, IDDST 2024. 4Riedl MA et al. AAAAI 2024. 5Riedl MA et al. BKS 2024. 6Maurer M et al. HAEi Workshop, 2022. 7Lesage et al. Int. Immunopharmacology, 2022. 8Crabbe et al, AAAAI 2021. 9Maurer M et al, AAAAI 2023. 10Maurer M et al. AAAAI 2023. 11Maurer M et al. BKS 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities. Deucrictibant XR Extended-release tablet Sustained absorption2 Maintains sustained therapeutic exposure over 24 hours3 from initial dose, allowing for once-daily oral treatment to prevent HAE attacks* Highly effective at preventing attacks*,4,5 Rapid protection2 and elimination6 Well-tolerated4,5 Easy of oral administration**,7 Deucrictibant IR Immediate-release capsule Rapid absorption6 Rapidly reaches therapeutic exposure within 15-30 minutes9, making it optimal for on-demand oral treatment of HAE attacks* Rapid onset of action11,12 Single dose resolution11 Ease of oral administration**,7

Slide 49

Bradykinin B2 receptor inhibition is broadly applicable across angioedema Source: Busse 2020 J Allergy Clin Immunol Pract; Bork et al 2021 J Allergy Clin Immunol; Zanichelli et al 2012 Allergy; Longhurst et al 2016 Clin. Exp. Immunol.; Otani, Banerji 2017 Immunol. Allergy Clin. N. Am.; Bova et al 2018 Int. Arch. Allergy Immunol.; Petersen et al 2024 J Allergy Clin Immunol; Shi et al 2021 Clin Immunol; Rashef et al 2024 J Allergy Clin Immunol Notes: bold = known or potential role for bradykinin involvement in disease. *also designated as Normal C1INH Angioedema (HAE-nC1INH); HMWK: high-molecular-weight kininogen; cHMWK: cleaved high-molecular-weight kininogen; FXII(a): Factor XII(a); ACE(i): angiotensin-converting enzyme (inhibitor); tPA: tissue plasminogen activator; KNG1: gene encoding HMWK; PLG: gene encoding plasminogen; FXII: gene encoding FXII; ANGPT: gene encoding angiopoietin; MYOF: gene encoding myoferlin; HSST: gene encoding heparan sulfate sulfotransferase; SCLS: systemic capillary leak syndrome Type/Endotype Mechanism Name/Acronym AE-MC Mast-cell mediated Mast cell degranulation AE-URT AE-ANA AE-BK Bradykinin mediated Hereditary C1INH deficiency HAE-C1INH (Type 1, 2) Acquired C1INH deficiency AAE-C1INH KKS pathway mutations HAE-FXII*, HAE-PLG*, HAE-KNG* AE-VE Vascular endothelium Intrinsic vascular endothelium dysfunction HAE-ANGPT*, HAE-MYOF*, HAE-HSST*, SCLS AE-DI Drug induced Drug adverse reactions (various mechanisms) AE-ACEI, AE-tPA, AE-DPPIV, AE-NSAID, etc. AE-UNK Unknown Unknown aetiology or mechanism AE-UNK, HAE-UNK*, EAE This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 50

Deucrictibant proof-of-concept in angioedema due to acquired C1-INH deficiency (AAE)1 Estimated prevalence of 1:100,000 to 1:500,000 or ~ 10% of HAE type 1/2 Currently, no therapies approved for AAE Investigator-initiated trial (IIT) by the Amsterdam UMC Source: 1Petersen RS et al. J Allergy Clin Immunol. 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 51

POP-AID investigator-initiated study: Deucrictibant prevention and treatment of acquired angioedema Source: 1Petersen RS et al. J Allergy Clin Immunol. 2024. This presentation includes data for an investigational product not yet approved by regulatory authorities. Attacks per month Patient 1 Patient 2 Patient 3 Baseline 1.2 1.2 0.9 Placebo 2.0 0.6 1.0 Deucrictibant 0 0 0 Antagonism of the bradykinin B2 receptor with deucrictibant has the potential to effectively and safely treat and prevent angioedema due to acquired C1-inhibitor deficiency

Slide 52

Rare allergy & immunology conditions (commercial) BK-mediated diseases (R&D) BK-mediated angioedema:  nC1, AAE Pharvaris aspires to leverage its foundational B2R expertise to develop therapies for conditions beyond HAE : HAE Type 1/2  This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 53

www.pharvaris.com NASDAQ: PHVS This presentation includes data for an investigational product not yet approved by regulatory authorities.

Slide 54

PHVS has the ambition to realize the potential of deucrictibant to become a preferred option for bradykinin-mediated conditions Source: 1Riedl MA et al. BKS 2024. 2Maurer M et al. BKS 2024. 3Company research. 4Petersen RS et al. J Allergy Clin Immunol. 2024. 5Lesage et al. Int. Immunopharmacology, 2022. HAE Long-term extension data1,2 reinforces our belief that deucrictibant has the potential to become a preferred option for the management of HAE AAE Based on the community’s interest3 and the initial intriguing data4, PHVS plans to pursue development of deucrictibant in AAE nC1 Leveraging B2-receptor mechanism5, potential for application to normal C1-INH hereditary angioedema